Dr. Walter J. Jessen works in the biopharma industry as a computational biologist. He curates knowledge on biomarkers and personalized medicine at BiomarkerCommons.org.
Consumers are becoming more technology savvy everyday. In many cases, disruptive innovation is providing tools more advanced than the most sophisticated commercial enterprises had just five years ago. Today, “smart customers” can see, learn about, and/or purchase almost anything, anytime, from anywhere. They research, connect, and purchase online with laptops, tablets, and smartphones without a second […]
An article discussing the burgeoning field of Computational Biology was just published on the Science Careers website. For the biopharmaceutical industry, big data is the abundant and ever-growing compendium of disease associations and genomic data that is (in many cases) publicly available. Instead of following the traditional pharma paradigm of systematically testing the effects of […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Selventa, a biomarker discovery company that enables personalized healthcare through the stratification of patients based on disease-driving mechanisms, recently announced a US patent that relates methods and techniques that facilitate discovery of biomarkers, thus aiding in the development of predictive and prognostic diagnostic tests for therapeutics targeting complex multi-factorial diseases. The Massachusetts-based company uses molecular […]
Earlier this month, Adam Bonislawski at GenomeWeb’s Proteomonitor reported that China-based BGI intends to expand its proteomics offerings and buy 50 new mass spectrometers over the next two years. This diversification into clinical and drug-development services is a forward-thinking move for the genomics/bioinformatics giant and one that should be taken seriously by current proteomics service […]